Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: FactSet

Seuraava tapahtuma
Sijoittajakalenteri ei ole saatavilla

Menneet tapahtumat
2025 Q3 -tulosraportti 24.11.2025
2025 Q2 -tulosraportti 17.7.2025
2024 Q3 -tulosraportti 7.11.2024
2023 Q4 -tulosraportti 15.5.2024
2023 Q3 -tulosraportti 20.11.2023

Asiakkaat katsoivat myös

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.

Kirjaudu

blueoceanguy
17.3.
·
blueoceanguy
17.3.
·
Received just this morning below. Very positive, and truly a growth case, both top- and bottom-line. ______________ "Cantourage Group SE / Key word(s): Annual Results/Preliminary Results Cantourage Group SE publishes preliminary figures for 2025 – Revenue rises to EUR 92.8 million 17.03.2026 CET/CEST Cantourage Group SE (ISIN: DE000A3DSV01) today published preliminary consolidated figures for the 2025 financial year. During the reporting period, the company achieved a significant increase in both revenue and earnings, thereby continuing its dynamic growth trajectory as one of the leading European companies in the field of medical cannabis. Group revenue increased to EUR 92.8 million in the 2025 financial year (previous year: EUR 50.9 million), representing growth of 82.3% compared to the previous year. Preliminary EBITDA rose to EUR 5.7 million (previous year: EUR 3.8 million). International expansion supports sustainable earnings quality Strategic expansion into selected core European markets is increasingly contributing to improved revenue and earnings. Business in the United Kingdom continued to develop positively and accounted for more than 20% of total group revenue in the 2025 financial year. The positioning of Cantourage Group SE as a pan-European pharmaceutical company is showing increasingly positive effects. Economies of scale, optimized supply chains, and a diversified market presence are stabilizing operational development. “The European medical cannabis market is increasingly entering a new phase of growth. With our scalable sourcing and distribution platform, exclusive supplier partnerships, and regulatory expertise, we are ideally positioned to benefit from this development. Our focus is on meeting rising demand in our core markets, further expanding our capacities, and establishing Cantourage as one of the leading companies in all relevant European medical markets,” explains Philip Schetter, CEO of Cantourage Group SE."
Heisann321
17.3.
·
Heisann321
17.3.
·
Thanks for sharing a lot of interesting information!
blueoceanguy
11.3.
·
blueoceanguy
11.3.
·
CANTOURAGE GROUP SE In light of the latest developments in the European cannabis industry, both NuWays and Montega, in connection with their coverage of Cantourage Group, have chosen to upgrade their price targets, which now lie in the range of EUR 8,00-10,00 per share. This reflects a potential price increase of approx. 70-90 % from the current level. The analysis coverage fully aligns with my own observations - and is possibly even a bit conservative compared to my personal estimate of EUR 10,00-12,00 per share at the current time. The analyses can be found at the following links: NuWays AG (published on 9. March 2026): https://cdn.prod.website-files.com/6640f5c21aec76e6d2026142/69afd9c9f30a9bf33e547314_Cantourage_Update.pdf Montega AG (published on 9. March 2026): https://cdn.prod.website-files.com/6640f5c21aec76e6d2026142/69aef696a4cfffe001fb1002_af05aa5c-e8db-4d6d-adda-ed4eb6810d16.pdf
blueoceanguy
11.3. · Muokattu
·
blueoceanguy
11.3. · Muokattu
·
Cantourage Group continues to appear very interesting, even after the recent share price increase. Looking at the recent M&A transaction in the industry, where their perhaps closest competitor Sanity Group was valued, the value in that deal is more than 2x Cantourage's current share price, and that notably solely based on the base price without including any earn-outs or upside mechanisms. If these elements are included, we are talking closer to up to 4x. It is also worth noting that Sanity Group is a significantly smaller company than Cantourage, which in my opinion only supports that Cantourage continues to be relatively undervalued in the market. I expect this to become more and more evident in the market's pricing over the coming weeks and months. Looking at the multiples in the comparable deal, a more reasonable valuation for Cantourage, in my assessment, should be somewhere in the range of EUR 10-12 on the conservative side and potentially EUR 22-24 per share, while the stock is currently trading around EUR 5.40.
blueoceanguy
6.3.
·
blueoceanguy
6.3.
·
For the curious (from Cantourage Group inbound): Numbers. Strategy. Impact. – CFO Roundtable Dear Sir or Madam, We are pleased to invite you to our virtual Roundtable with Cantourage Group SE. During the event, Philip Schetter, CEO of Cantourage Group SE, will provide a brief update on the company’s development in 2026 (ytd), including key operational milestones and the current regulatory status quo in Europe – with a particular focus on the German medical cannabis market. In addition, the company's new CFO Monique Jaqqam will introduce herself and outline the most important strategic and financial measures for the coming months. Participants will have the opportunity to ask questions and exchange views on opportunities, challenges, and trends in the rapidly evolving medical cannabis sector. We look forward to your participation. Date: March 9, 2026 Time: 9:30am (CET) Duration: 1 hour Language: Englisch Registration: https://www.appairtime.com/event/12d7c480-5d17-4a62-a19a-c0551ef3d6fb
blueoceanguy
3.3.
·
blueoceanguy
3.3.
·
An early Christmas wish for closer coverage on both the buy-side and the sell-side. I'm sure it will come.

Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Uutiset

Ei uutisia tällä hetkellä

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Tuotteita joiden kohde-etuutena tämä arvopaperi

2025 Q3 -tulosraportti

124 päivää sitten

Uutiset

Ei uutisia tällä hetkellä

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.

Kirjaudu

blueoceanguy
17.3.
·
blueoceanguy
17.3.
·
Received just this morning below. Very positive, and truly a growth case, both top- and bottom-line. ______________ "Cantourage Group SE / Key word(s): Annual Results/Preliminary Results Cantourage Group SE publishes preliminary figures for 2025 – Revenue rises to EUR 92.8 million 17.03.2026 CET/CEST Cantourage Group SE (ISIN: DE000A3DSV01) today published preliminary consolidated figures for the 2025 financial year. During the reporting period, the company achieved a significant increase in both revenue and earnings, thereby continuing its dynamic growth trajectory as one of the leading European companies in the field of medical cannabis. Group revenue increased to EUR 92.8 million in the 2025 financial year (previous year: EUR 50.9 million), representing growth of 82.3% compared to the previous year. Preliminary EBITDA rose to EUR 5.7 million (previous year: EUR 3.8 million). International expansion supports sustainable earnings quality Strategic expansion into selected core European markets is increasingly contributing to improved revenue and earnings. Business in the United Kingdom continued to develop positively and accounted for more than 20% of total group revenue in the 2025 financial year. The positioning of Cantourage Group SE as a pan-European pharmaceutical company is showing increasingly positive effects. Economies of scale, optimized supply chains, and a diversified market presence are stabilizing operational development. “The European medical cannabis market is increasingly entering a new phase of growth. With our scalable sourcing and distribution platform, exclusive supplier partnerships, and regulatory expertise, we are ideally positioned to benefit from this development. Our focus is on meeting rising demand in our core markets, further expanding our capacities, and establishing Cantourage as one of the leading companies in all relevant European medical markets,” explains Philip Schetter, CEO of Cantourage Group SE."
Heisann321
17.3.
·
Heisann321
17.3.
·
Thanks for sharing a lot of interesting information!
blueoceanguy
11.3.
·
blueoceanguy
11.3.
·
CANTOURAGE GROUP SE In light of the latest developments in the European cannabis industry, both NuWays and Montega, in connection with their coverage of Cantourage Group, have chosen to upgrade their price targets, which now lie in the range of EUR 8,00-10,00 per share. This reflects a potential price increase of approx. 70-90 % from the current level. The analysis coverage fully aligns with my own observations - and is possibly even a bit conservative compared to my personal estimate of EUR 10,00-12,00 per share at the current time. The analyses can be found at the following links: NuWays AG (published on 9. March 2026): https://cdn.prod.website-files.com/6640f5c21aec76e6d2026142/69afd9c9f30a9bf33e547314_Cantourage_Update.pdf Montega AG (published on 9. March 2026): https://cdn.prod.website-files.com/6640f5c21aec76e6d2026142/69aef696a4cfffe001fb1002_af05aa5c-e8db-4d6d-adda-ed4eb6810d16.pdf
blueoceanguy
11.3. · Muokattu
·
blueoceanguy
11.3. · Muokattu
·
Cantourage Group continues to appear very interesting, even after the recent share price increase. Looking at the recent M&A transaction in the industry, where their perhaps closest competitor Sanity Group was valued, the value in that deal is more than 2x Cantourage's current share price, and that notably solely based on the base price without including any earn-outs or upside mechanisms. If these elements are included, we are talking closer to up to 4x. It is also worth noting that Sanity Group is a significantly smaller company than Cantourage, which in my opinion only supports that Cantourage continues to be relatively undervalued in the market. I expect this to become more and more evident in the market's pricing over the coming weeks and months. Looking at the multiples in the comparable deal, a more reasonable valuation for Cantourage, in my assessment, should be somewhere in the range of EUR 10-12 on the conservative side and potentially EUR 22-24 per share, while the stock is currently trading around EUR 5.40.
blueoceanguy
6.3.
·
blueoceanguy
6.3.
·
For the curious (from Cantourage Group inbound): Numbers. Strategy. Impact. – CFO Roundtable Dear Sir or Madam, We are pleased to invite you to our virtual Roundtable with Cantourage Group SE. During the event, Philip Schetter, CEO of Cantourage Group SE, will provide a brief update on the company’s development in 2026 (ytd), including key operational milestones and the current regulatory status quo in Europe – with a particular focus on the German medical cannabis market. In addition, the company's new CFO Monique Jaqqam will introduce herself and outline the most important strategic and financial measures for the coming months. Participants will have the opportunity to ask questions and exchange views on opportunities, challenges, and trends in the rapidly evolving medical cannabis sector. We look forward to your participation. Date: March 9, 2026 Time: 9:30am (CET) Duration: 1 hour Language: Englisch Registration: https://www.appairtime.com/event/12d7c480-5d17-4a62-a19a-c0551ef3d6fb
blueoceanguy
3.3.
·
blueoceanguy
3.3.
·
An early Christmas wish for closer coverage on both the buy-side and the sell-side. I'm sure it will come.

Tarjoustasot

Xetra

Määrä

Osto

Myynti

Määrä

Viimeisimmät kaupat

Aika	Hinta	Määrä	Ostaja	Myyjä
-		-	-	-

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Asiakkaat katsoivat myös

Yhtiötapahtumat

Datan lähde: FactSet

Seuraava tapahtuma
Sijoittajakalenteri ei ole saatavilla

Menneet tapahtumat
2025 Q3 -tulosraportti 24.11.2025
2025 Q2 -tulosraportti 17.7.2025
2024 Q3 -tulosraportti 7.11.2024
2023 Q4 -tulosraportti 15.5.2024
2023 Q3 -tulosraportti 20.11.2023

Tuotteita joiden kohde-etuutena tämä arvopaperi

2025 Q3 -tulosraportti

124 päivää sitten

Uutiset

Ei uutisia tällä hetkellä

Yhtiötapahtumat

Datan lähde: FactSet

Seuraava tapahtuma
Sijoittajakalenteri ei ole saatavilla

Menneet tapahtumat
2025 Q3 -tulosraportti 24.11.2025
2025 Q2 -tulosraportti 17.7.2025
2024 Q3 -tulosraportti 7.11.2024
2023 Q4 -tulosraportti 15.5.2024
2023 Q3 -tulosraportti 20.11.2023

Tuotteita joiden kohde-etuutena tämä arvopaperi

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.

Kirjaudu

blueoceanguy
17.3.
·
blueoceanguy
17.3.
·
Received just this morning below. Very positive, and truly a growth case, both top- and bottom-line. ______________ "Cantourage Group SE / Key word(s): Annual Results/Preliminary Results Cantourage Group SE publishes preliminary figures for 2025 – Revenue rises to EUR 92.8 million 17.03.2026 CET/CEST Cantourage Group SE (ISIN: DE000A3DSV01) today published preliminary consolidated figures for the 2025 financial year. During the reporting period, the company achieved a significant increase in both revenue and earnings, thereby continuing its dynamic growth trajectory as one of the leading European companies in the field of medical cannabis. Group revenue increased to EUR 92.8 million in the 2025 financial year (previous year: EUR 50.9 million), representing growth of 82.3% compared to the previous year. Preliminary EBITDA rose to EUR 5.7 million (previous year: EUR 3.8 million). International expansion supports sustainable earnings quality Strategic expansion into selected core European markets is increasingly contributing to improved revenue and earnings. Business in the United Kingdom continued to develop positively and accounted for more than 20% of total group revenue in the 2025 financial year. The positioning of Cantourage Group SE as a pan-European pharmaceutical company is showing increasingly positive effects. Economies of scale, optimized supply chains, and a diversified market presence are stabilizing operational development. “The European medical cannabis market is increasingly entering a new phase of growth. With our scalable sourcing and distribution platform, exclusive supplier partnerships, and regulatory expertise, we are ideally positioned to benefit from this development. Our focus is on meeting rising demand in our core markets, further expanding our capacities, and establishing Cantourage as one of the leading companies in all relevant European medical markets,” explains Philip Schetter, CEO of Cantourage Group SE."
Heisann321
17.3.
·
Heisann321
17.3.
·
Thanks for sharing a lot of interesting information!
blueoceanguy
11.3.
·
blueoceanguy
11.3.
·
CANTOURAGE GROUP SE In light of the latest developments in the European cannabis industry, both NuWays and Montega, in connection with their coverage of Cantourage Group, have chosen to upgrade their price targets, which now lie in the range of EUR 8,00-10,00 per share. This reflects a potential price increase of approx. 70-90 % from the current level. The analysis coverage fully aligns with my own observations - and is possibly even a bit conservative compared to my personal estimate of EUR 10,00-12,00 per share at the current time. The analyses can be found at the following links: NuWays AG (published on 9. March 2026): https://cdn.prod.website-files.com/6640f5c21aec76e6d2026142/69afd9c9f30a9bf33e547314_Cantourage_Update.pdf Montega AG (published on 9. March 2026): https://cdn.prod.website-files.com/6640f5c21aec76e6d2026142/69aef696a4cfffe001fb1002_af05aa5c-e8db-4d6d-adda-ed4eb6810d16.pdf
blueoceanguy
11.3. · Muokattu
·
blueoceanguy
11.3. · Muokattu
·
Cantourage Group continues to appear very interesting, even after the recent share price increase. Looking at the recent M&A transaction in the industry, where their perhaps closest competitor Sanity Group was valued, the value in that deal is more than 2x Cantourage's current share price, and that notably solely based on the base price without including any earn-outs or upside mechanisms. If these elements are included, we are talking closer to up to 4x. It is also worth noting that Sanity Group is a significantly smaller company than Cantourage, which in my opinion only supports that Cantourage continues to be relatively undervalued in the market. I expect this to become more and more evident in the market's pricing over the coming weeks and months. Looking at the multiples in the comparable deal, a more reasonable valuation for Cantourage, in my assessment, should be somewhere in the range of EUR 10-12 on the conservative side and potentially EUR 22-24 per share, while the stock is currently trading around EUR 5.40.
blueoceanguy
6.3.
·
blueoceanguy
6.3.
·
For the curious (from Cantourage Group inbound): Numbers. Strategy. Impact. – CFO Roundtable Dear Sir or Madam, We are pleased to invite you to our virtual Roundtable with Cantourage Group SE. During the event, Philip Schetter, CEO of Cantourage Group SE, will provide a brief update on the company’s development in 2026 (ytd), including key operational milestones and the current regulatory status quo in Europe – with a particular focus on the German medical cannabis market. In addition, the company's new CFO Monique Jaqqam will introduce herself and outline the most important strategic and financial measures for the coming months. Participants will have the opportunity to ask questions and exchange views on opportunities, challenges, and trends in the rapidly evolving medical cannabis sector. We look forward to your participation. Date: March 9, 2026 Time: 9:30am (CET) Duration: 1 hour Language: Englisch Registration: https://www.appairtime.com/event/12d7c480-5d17-4a62-a19a-c0551ef3d6fb
blueoceanguy
3.3.
·
blueoceanguy
3.3.
·
An early Christmas wish for closer coverage on both the buy-side and the sell-side. I'm sure it will come.

Tarjoustasot

Xetra

Määrä

Osto

Myynti

Määrä

Viimeisimmät kaupat

Aika	Hinta	Määrä	Ostaja	Myyjä
-		-	-	-

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Tietoa osakekaupankäyntiin liittyvistä riskeistä

Tietoa osakekaupankäyntiin liittyvistä riskeistä

Tietoa osakekaupankäyntiin liittyvistä riskeistä

Tietoa osakekaupankäyntiin liittyvistä riskeistä

Tietoa osakekaupankäyntiin liittyvistä riskeistä

Tietoa osakekaupankäyntiin liittyvistä riskeistä